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BACKGROUND AND PURPOSE
Asthma exacerbations contribute to corticosteroid insensitivity. LPS is ubiquitous in the environment. It causes
bronchoconstriction and airway inflammation and may therefore exacerbate allergen responses. This study examined whether
LPS and ovalbumin co-administration could exacerbate the airway inflammatory and functional responses to ovalbumin in
conscious guinea pigs and whether these exacerbated responses were insensitive to inhaled corticosteroid treatment with
fluticasone propionate (FP).
EXPERIMENTAL APPROACH
Guinea pigs were sensitized and challenged with ovalbumin and airway function recorded as specific airway conductance by
whole body plethysmography. Airway inflammation was measured from lung histology and bronchoalveolar lavage. Airway
hyper-reactivity (AHR) to inhaled histamine was examined 24 h after ovalbumin. LPS was inhaled alone or 24 or 48 h before
ovalbumin and combined with ovalbumin. FP (0.05–1 mg·mL−1) or vehicle was nebulized for 15 min twice daily for 6 days
before ovalbumin or LPS exposure.
KEY RESULTS
Ovalbumin inhalation caused early (EAR) and late asthmatic response (LAR), airway hyper-reactivity to histamine and influx of
inflammatory cells into the lungs. LPS 48 h before and co-administered with ovalbumin exacerbated the response with
increased length of the EAR, prolonged response to histamine and elevated inflammatory cells. FP 0.5 and 1 mg·mL−1 reduced
the LAR, AHR and cell influx with ovalbumin alone, but was ineffective when guinea pigs were exposed to LPS before and
with ovalbumin.
CONCLUSIONS AND IMPLICATIONS
LPS exposure exacerbates airway inflammatory and functional responses to allergen inhalation and decreases corticosteroid
sensitivity. Its widespread presence in the environment could contribute to asthma exacerbations and corticosteroid
insensitivity in humans.
Abbreviations
AHR, airway hyper-responsiveness; EAR, early asthmatic response; FP, fluticasone propionate; LAR, late asthmatic
response; Ova, ovalbumin; sGaw, specific airway conductance
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Introduction
Asthma exacerbations are worsening of respiratory symptoms
characterized by increased airflow obstruction, mucus and
oedema (Dougherty and Fahy, 2009). LPS from Gram-
negative bacteria, also found ubiquitously in the environ-
ment in textiles, milk, tobacco smoke and particulate air
pollution, is an important contributor to asthma exacerba-
tions. LPS exposure evokes persistent bronchoconstriction
(Michel et al., 1989) and can modify the early (EAR) and late
asthmatic responses (LAR) of asthmatics to allergen chal-
lenge, with more neutrophils than seen with allergen alone
(Hunt et al., 1994). A significant increase in eosinophil and
neutrophil cell counts (Eldridge and Peden, 2000) and of
airway hyper-responsiveness (AHR) in asthmatics (Boehlecke
et al., 2003) was observed following combined dust mite and
LPS challenges. Associated with neutrophilia are increases in
cytokines such as IL-8 and IL-17 (Doe et al., 2010).
Paradoxically, LPS is also protective, with early life expo-
sure decreasing allergy in later life (von Mutius, 2001). High
doses (10–50 μg·mL−1) of LPS attenuate the development of
allergic responses to ovalbumin (Ova) when administered
during or close to allergen challenge (Tulic´ et al., 2000); high
doses (1–20 μg·mL−1) of LPS have been demonstrated not only
to suppress allergen-induced AHR and neutrophilic inflam-
mation (Rodríguez et al., 2003; Delayre-Orthez et al., 2004;
Murakami et al., 2007) but also to decrease AHR and inflam-
mation (Tulic et al., 2002). In contrast, low doses (0.001–
0.1 μg·mL−1) of LPS promote allergy when used as an adjunct
to sensitization (Eisenbarth et al., 2002) or when adminis-
tered during Ova challenge (Delayre-Orthez et al., 2004).
However, higher doses of LPS have also been demonstrated to
increase pulmonary inflammation (Komlósi et al., 2006)
while attenuating functional responses to allergens (Vannier
et al., 1991). LPS combined with Ova challenge can both
increase and decrease mucus secretion depending on the LPS
dose (Dong et al., 2009).
Inhaled corticosteroids are a frontline therapy in asthma
treatment and are very effective at diminishing inflammatory
and functional responses to allergen (Palmqvist et al., 2005).
In a guinea pig model mimicking human asthma (Ricciardolo
et al., 2008), the inhaled corticosteroid fluticasone propionate
(FP) abolished the LAR, suppressed AHR and significantly
reduced eosinophils (Evans et al., 2012). Subsets of asthmatic
patients demonstrate decreased sensitivity to inhaled corti-
costeroids (Szefler et al., 2002). The origin of corticosteroid
insensitivity is unknown, but mechanisms related to changes
induced by LPS may be involved. Corticosteroid-insensitive
asthmatics demonstrate inflammatory patterns characteristic
of LPS activation, coinciding with high levels of LPS in lavage
fluid (Goleva et al., 2008). Additionally, LPS alone induces
neutrophilic inflammation that is unresponsive to inhaled
corticosteroid treatment in healthy volunteers and asthmat-
ics (Trapp et al., 1998; Michel et al., 2000). In animal models,
the effect of combining allergen challenge with LPS on cor-
ticosteroid sensitivity has only been evaluated in one study
using systemically administered dexamethasone (Komlósi
et al., 2006). Moreover, LPS effects on the early and LARs have
not been assessed in animal models. Thus, LPS appears to
offer a means of altering the sensitivity of allergen-induced
inflammation to corticosteroids and provide an animal
model of steroid insensitivity. In the present study, we
examine the hypothesis that LPS exposure modifies the func-
tional and inflammatory responses of guinea pigs to allergen.
Because the precise effects of LPS exposure on allergen
responses appear to vary, we first examined the timing and
number of LPS exposures upon the functional and inflamma-
tory responses to Ova in sensitized guinea pigs. In view of the
inconsistent literature data on whether high or low doses
enhanced or suppressed the allergen responses, we chose a
relatively high dose (30 μg·mL−1) for these studies.
Methods
All chemicals were obtained from Sigma-Aldrich, Gillingham,
Dorset, UK, or Fisher-Scientific, Loughborough, UK, unless
stated otherwise.
Animal husbandry
Male Dunkin-Hartley guinea pigs (total 134, 200–300 g;
Charles River, Sulzfeld, Germany) were housed in pathogen-
free conditions with 12 h light/dark cycles and allowed water
and laboratory chow ad libitum. The total number of animals
used was 134. They were provided with environmental
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enrichment with cardboard tubes and hay. All procedures
were carried out in accordance with the Animals (Scientific
Procedures) Act of 1986 and underwent ethical review by
Cardiff University Biological Standards Committee. The
ARRIVE guidelines on Animal Research: Reporting In Vivo
Experiments have been adhered to in the design and execu-
tion of the study (Kilkenny et al., 2010; McGrath et al., 2010).
Ovalbumin sensitization
Guinea pigs were sensitized by bilateral i.p. injection of Ova
(VWR, Lutterworth, Leics, UK; technical grade 98.8% purity,
150 μg) and Al(OH)3 (100 mg) in 1 mL of normal saline on
days 1, 4 and 7.
Inhalation challenge with Ova and LPS
Sensitized guinea pigs were exposed to inhaled Ova
(300 μg·mL−1) on day 21. LPS (30 μg·mL−1) or normal saline
exposure was by two protocols: 72 and 24 h pre-Ova exposure
(Figure 1A), 48 h pre-Ova and co-administered with Ova
(Figure 1B). Non-sensitized guinea pigs were exposed to LPS
(30 μg·mL−1) or saline on days 5 and 7 (Figure 1C). Ova, LPS or
saline was delivered into a Perspex exposure chamber (15 × 30
× 15 cm) for 1 h using a DeVilbiss (Somerset, Pennsylvania,
PA, USA) nebulizer at 0.3 mL·min−1 and pressure of 20 lb p.s.i.
Measurement of lung function
Airway function was measured as specific airway conductance
(sGaw) in conscious, spontaneously breathing guinea pigs by
non-invasive double-chamber plethysmography (Buxco
Systems, Wilmington, NC, USA) (Now Data Sciences Interna-
tional, The Netherlands). Lung function was recorded follow-
ing the final Ova, LPS or saline challenges at intervals for 12
and at 24 h.
Figure 1
Ova and LPS protocols used in the present study. (A) Pre-Ova challenge LPS administration. (B) LPS and Ova co-administration. (C) LPS without
Ova protocol.
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Airway responses to aerosolized histamine were deter-
mined pre- and 24 h post-Ova or the final LPS/saline chal-
lenge using whole body plethysmography. Histamine
(0.3 mM, 2 min) was delivered by the use of a Buxco nebu-
lizer chamber at 0.5 L·min−1 and 10% duty (% every 6 s of
nebulizing) per chamber. This nebulizer protocol evokes
small non-significant bronchoconstriction in naïve guinea
pigs. Lung function was measured before histamine inhala-
tion and at 0, 5 and 10 min afterwards.
Pulmonary inflammation and cytokines
Following the final histamine challenge, guinea pigs were
administered an overdose of sodium pentobarbitone
(Euthatal, 400 mg·kg–1 i.p.). Bronchoalveolar lavage was per-
formed using normal saline (1 mL per 100 g) instilled for
3 min through a polypropylene cannula inserted into the
trachea. This process was repeated, the samples pooled and the
total number of cells·mL–1 counted using a Neubauer haemo-
cytometer (Sigma-Aldrich). Differential cell counts (eosino-
phils, macrophages, lymphocytes and neutrophils) were
performed after centrifuging 100 μL of lavage fluid onto glass
microscope slides using a Shandon Cytospin (ThermoFisher
Scientific, Hemel Hempstead, UK) at 110 x g for 7 min. Slides
were subsequently stained with 1.5% Leishman’s solution in
100% methanol for 6 min. A minimum of 200 cells were
counted. Protein content in lavage fluid was determined as a
measure of airway oedema by use of the BCA protein assay
(Thermo Scientific Pierce Protein Biology, Cramlington,
Northumberland, UK). One hundred milligrams of right
middle lung lobe was homogenized in 1 mL lysis buffer
(Thomas et al., 2006) using a Precellys® 24 tissue homog-
enizer (Stretton Scientific Ltd, Stretton, Derbyshire, UK) for 3 ×
20 s cycles at 5500 r.p.m. Levels of IL-8, IL-17 and IL-13 were
measured in diluted homogenized lung samples using human
antibody ELISA kits (R&D Systems, Abington, UK) once cross-
reactivity was established. The limit of detection for IL-13 was
47 pg·mL−1, for IL-17 was 16 pg·mL−1 and for IL-8 31 pg·mL−1.
Cytokine levels were adjusted for total lung protein and
expressed as pg·mg−1 lung protein.
Histology
Lung lobes were stored in formaldehyde and 1–2 mm bilat-
eral sections were cut and dehydrated in increasing concen-
trations of alcohol and then chloroform. Tissue sections were
set into paraffin wax blocks, 5 μm sections were cut using a
microtome and fixed to poly-L-lysine-coated slides. Sections
were deparaffinized with Histoclear® (Fisher Scientific) (3 × 5
min periods), rehydrated through graded ethanol (100% 2 × 3
min, 90% 3 min and 70% 3 min), washed under running tap
water rinsed with distilled water and stained with Mayer’s
haematoxylin (2 min). Slides were then rinsed with water and
stained with 1% eosin (90 s) before dehydration with graded
ethanol and clearing with Histoclear (3 × 5 min periods)
followed by air drying for 24 h and mounting with Histo-
mount® (Life Technologies, Paisley, UK) and applying a cov-
erslip. A semi-quantitative scoring method was applied to two
airways per animal for assessment of general lung morphol-
ogy by a blinded observer. 0 = normal lung; 1 = minimal
peribronchiolar (PB) inflammation; 2 = slight inflammation
in PB area; 3 = moderate PB inflammation; 4 = marked PB
inflammation and cuffing (thickening), slight loss of lung
structure; 5 = severe PB inflammation, cuffing and infiltra-
tion, loss of lung structure (Barends et al., 2004). Sections
were also stained with Alcian blue/periodic acid Schiff (Ab/
PAS) for assessment of goblet cell numbers in airway epithe-
lium (Evans et al., 2012). After the sections were
deparaffinized with Histoclear, rehydrated through graded
alcohol and rinsed with water as described earlier, they were
stained with 1% Alcian blue dissolved in 3% aqueous acetic
acid (pH 2.5, 5 min) followed by washing under running tap
water (5 min) and then with distilled water (5 min). Sections
were then stained with periodic acid (0.5%, 5 min), rinsed
with water and Schiff’s reagent added (10 min) before a
further rinse under running tap water and staining with
Mayer’s haematoxylin (20 s). Finally, they were rinsed with
water (5 min), dehydrated through graded ethanol, cleared
with Histoclear (3 × 5 min periods) followed by air drying
before Histomount and then a coverslip were applied.
Drug administration
FP (0.5 or 1 mg·mL−1) or vehicle [ethanol (30%), DMSO (30%)
and saline (40%)] was nebulized for 15 min twice daily into
an in-house Perspex exposure chamber using a DeVilbiss
nebulizer from days 16 to 21 in Ova protocols and days 2 to
7 in LPS-only protocols. Two additional FP doses (0.05 and
0.1 mg·mL−1) were used in the Ova alone protocol.
Data analysis
Lung function data were plotted as a percentage of baseline to
take into account the individual differences in guinea pig
baseline sGaw values. To account for differences in the timing
and duration of allergen responses, sGaw was also expressed as
the peak bronchoconstriction during the early (0–6 h) and
late (6–12 h) phases and as AUC. The duration of the EAR was
analysed as the time to return to 50% of peak EAR sGaw
values. Results are plotted as the mean ± SEM. Student’s t-tests
were used to compare groups or data points. One-way ANOVA
followed by Dunnett’s post hoc test were used when two or
more groups were compared with a control group. P-values
less than 0.05 were considered significant. A non-parametric
Kruskal–Wallis ANOVA test was used to analyse IL-8 levels,
which were not detected in all samples.
Results
Effect of LPS on Ova-induced
functional responses
Ova challenge with saline pretreatment (saline/saline/Ova)
induced distinct EAR (−73.5 ± 1.9%) and LAR (−24.0 ± 4.7%)
(Figure 2A). A single LPS exposure, 24 h before Ova, and
two LPS exposures, 72 and 24 h before Ova, attenuated
the early phase, significantly decreasing the peak EAR to
−34.4 ± 4.6 and −25.2 ± 27.7% respectively (Figure 2A). The
LAR was unchanged by the two LPS pretreatments. In
co-administration protocols, neither a single LPS exposure
co-administered with Ova (saline/LPS + Ova) nor two LPS
treatments, one administered 48 h before Ova challenge and
one co-administered with Ova (LPS/LPS + Ova), altered either
the peak EAR or LAR (Figure 2B). However, the latter protocol
BJPEffects of LPS in a guinea pig model of asthma
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Figure 2
The mean time courses for changes in sGaw following Ova challenge of Ova-sensitized guinea pigs. Guinea pigs were treated with either saline
or 30 μg·mL−1 LPS for 1 h, (A) 72 h and 24 h pre-Ova challenge, or (B) 48 h before Ova challenge and co-administered with Ova. Histograms
represent the maximum bronchoconstriction values recorded during the EAR (0–6 h) and LAR (6–12 h). (C) Analysis of the time taken for EAR to
recover to 50% of peak bronchoconstriction values. (D) Mean time courses for changes in sGaw following the second of two LPS or saline
exposures in non-sensitized guinea pigs. Mean changes in sGaw are expressed as mean ± SEM percentage change from baseline prior to
Ova challenge. n = 5–10. *Significantly different from respective naïve or Ova challenge and double-saline treatment group P < 0.05, **P < 0.01,
***P < 0.001; performed with one-way ANOVA followed by Bonferroni post-test.
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did increase the duration of the EAR (4.8 ± 0.6 h compared
with saline 2.3 ± 0.7 h) (Figure 2C). This effect was not seen in
pre-Ova LPS exposure protocols. At 24 h post-Ova sGaw values
had returned to baseline. LPS alone evoked a significant
immediate bronchoconstriction peaking at 2 h (−41.3 ± 2.7%
compared with saline −22.5 ± 4.5%) and returning to baseline
after 5 h (Figure 2D).
Effect of LPS on Ova-induced AHR
Ova challenge with no LPS treatment (saline/saline/Ova) sig-
nificantly increased the bronchoconstriction to histamine
compared with pre-challenge values, indicating the develop-
ment of AHR (Figure 3A). With a single LPS exposure before
Ova challenge (saline/LPS/Ova), there was still a significant
increase in the histamine response (Figure 3B). However, two
LPS exposures (LPS/LPS/Ova) abolished the development of
AHR to histamine (Figure 3C). In the co-administration pro-
tocols (Figure 3E,F), Ova challenge with one LPS co-exposure
(saline/LPS + Ova) or with two LPS exposures produced bron-
choconstrictions to histamine. However, these bronchocon-
strictions continued to increase over the next 10 min and
were therefore more prolonged and significantly greater than
in controls exposed to Ova and two saline challenges
(Figure 3D). LPS alone increased the histamine bronchocon-
striction at 0 min (−14.1 ± 3.8% compared with pre-LPS −0.9
± 1.0%) and continued for 10 min (−16.1 ± 4.7% compared
with pre-LPS −1.0 ± 2.5%) (not shown).
Effect of LPS on Ova-induced
pulmonary inflammation
Ova challenge with no LPS exposure significantly increased
total cells and all cell types in lavage fluid compared with naïve
animals (Figure 4). Total cell numbers (Figure 4A) further
increased with additional LPS exposure, reaching significance
after two doses of LPS in both pre-Ova and co-administration
protocols. This change mainly reflected increases in neutrophils
(Figure 4E) occurring with two doses of LPS in both pre-Ova and
co-administration protocols. Macrophages (Figure 4B) were
also significantly increased with two doses of LPS in both the
pre-Ova (LPS/LPS/Ova) and co-administration (LPS/LPS + Ova)
protocols (Figure 4B). Eosinophils (Figure 4C) and lymphocytes
(Figure 4D) were unchanged by LPS treatment compared with
the effect of Ova alone. IL-13 levels (Figure 4F) increased signifi-
cantly following Ova exposure compared with naïve animals.
LPS exposure did not significantly increase IL-13 levels further
in any protocol, although there was a significant reduction with
a single pre-Ova exposure (saline/LPS/Ova). IL-8 (Figure 4G)
was significantly increased in LPS and Ova co-administration
groups exposed to one and two LPS exposures compared with
Ova and saline. IL-17 levels (Figure 4H) significantly increased
following Ova exposure compared with naïve animals. LPS
treatment did not change IL-17 levels compared with Ova +
saline in any protocol. Total lavage protein (Figure 4I) signifi-
cantly increased after Ova challenge alone compared with naïve
animals. Only with two LPS exposures in the co-administration
protocol was there a further significant increase.
LPS alone (two exposures 48 h apart) in non-sensitized
guinea pigs significantly increased total cells compared with
two exposures with saline (Figure 4A) as well as macrophages
(Figure 4B) and neutrophils (Figure 4E). LPS also significantly
increased IL-8 (Figure 4G) compared with saline treatment
where it was undetectable. These levels of macrophages, neu-
trophils and IL-8 appeared to be higher than with the LPS/
LPS + Ova combinations, although not significantly.
Effect of Ova and LPS on airway histology
and goblet cell meta/hyperplasia
Figure 5A–C shows lung sections stained with haematoxylin
and eosin for assessment of general morphology. Ova chal-
lenge with saline treatment increased the staining for
inflammatory cells in the peribronchiolar (PB) area
(Figure 5C). LPS did not further change the inflammatory
cell presence in the bronchiole in any protocol (LPS/
LPS + Ova; Figure 5D). LPS alone significantly increased the
mean pathology score compared with saline exposure.
Figure 5E–H shows the lung sections stained with Alcian
blue/periodic acid to reveal mucus-containing goblet cells.
Guinea pigs treated with saline before Ova challenge (saline/
saline/Ova) showed increased numbers of goblet cells
(Figure 5G). Treatment with LPS and Ova further increased
the number of goblet cells. Figure 5J represents the number
of mucin-associated goblet cells per 10 000 pixels of epithe-
lium. In the pre-Ova administration protocol, two exposures
to LPS significantly increased goblet cells compared with
naïve. In the co-administration protocol, LPS exposure
before and co-administered with Ova (LPS/LPS + Ova) sig-
nificantly increased goblet cells compared with naïve and to
Sal/LPS + Ova. LPS alone significantly increased goblet cell
numbers compared with saline.
Sensitivity of functional responses to
inhaled FP
The effects of FP were only examined in the LPS pre- and
co-administration model. Ova challenge of vehicle-treated
guinea pigs caused an EAR and LAR (Figure 6A). No decrease
in the LAR was observed with 0.05 or 0.1 mg·mL−1 FP (data
not shown). Treatment with 0.5 and 1 mg·mL−1 FP signifi-
cantly attenuated the LAR. This was reflected in a decrease
both in the 6−12 h peak response and in the AUC between 6
and 12 h for both 0.5 and 1 mg·mL−1 FP compared with
vehicle (Figure 6C). The peak EAR (0−6 h) after Ova challenge
was not inhibited by 0.5 and 1 mg·mL−1 FP, but the 0−6 h
AUC was inhibited due to smaller bronchoconstrictions
between 1 and 6 h. In the combined Ova and LPS challenge
protocols (LPS/LPS + Ova; Figure 6B), a LAR and prolonged
EAR were observed. The longer EAR was illustrated by the
time to recover to 50% being significantly extended
(Figure 6D). FP 0.5 mg·mL−1 treatment did not significantly
alter the time course or attenuate the peak of the LAR. FP
1 mg·mL−1 appeared to reduce the LAR, but this was not
significant when assessed from the 6−12 h AUC. Neither dose
of FP significantly reduced the prolonged EAR response meas-
ured as the time to recover to 50% (Figure 6D). After LPS
alone, vehicle-treated groups demonstrated a peak broncho-
constriction between 0 and 12 h, which was not significantly
attenuated by FP treatment (Figure 6C).
Sensitivity of AHR to inhaled FP
Ova challenge of vehicle-treated guinea pigs induced AHR, as
a significant increase in the bronchoconstrictor response to
histamine post-Ova compared with pre-Ova challenge
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(Figure 7A). Treatment with 0.05 and 0.1 mg·mL−1 FP did not
attenuate this increased response. Treatment with 0.5 (data
not shown) or 1 mg·mL−1 FP (Figure 7B) abolished the devel-
opment of AHR. In Ova and LPS challenge protocols, vehicle-
treated groups displayed a bronchoconstriction to histamine
post-Ova challenge that increased across the 10 min of meas-
urement (Figure 7C). FP 0.5 (not shown) and 1 mg·mL−1 treat-
ment did not significantly alter this response with
significant bronchoconstrictions still present at 10 min
(Figure 7D). When challenged with LPS alone, vehicle-treated
groups displayed a small increase in bronchoconstrictor
response to histamine significant at 10 min compared with
Figure 3
Response of the airways to nebulized histamine (0.3 mM, 2 min) before and 24 h after Ova challenge of Ova-sensitized guinea pigs. Guinea pigs
were treated 72 and 24 h pre-Ova with: (A) saline twice, (B) saline and LPS (30 μg·mL−1), (C) LPS twice, or treated 48 h pre-Ova and with Ova
challenge with (D) saline twice, (E) saline and LPS (F) LPS twice. Mean changes in sGaw are expressed as mean ± SEM percentage change from
baseline. A negative value represents a bronchoconstriction. n = 5–10. *Significantly different from pre-Ova challenge values P < 0.05, **P < 0.01,
***P < 0.001; performed with a two-tailed t-test.
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pre-challenge (Figure 7E). The peak response to histamine for
the entire 10 min was significantly increased (−22.0 ± 5.2%)
compared with pre-LPS responses (−7.0 ± 1.8%). Treatment
with 0.5 (data not shown) and 1 mg·mL−1 FP did not abolish
the development of AHR, with a significant increase in sGaw at
5 min post-histamine compared with pre-LPS. However, the
peak response to histamine was no longer significantly
greater than the pre-challenge peak (Figure 7F).
Figure 4
The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) counts in bronchoalveolar fluid and IL-13 (F), IL-8 (G) IL-17
(H) in homogenized lung and lavage fluid protein levels (I) of Ova-sensitized guinea pigs determined 24 h after Ova challenge. Guinea pigs were
treated with either saline or 30 μg·mL−1 LPS for 1 h either 72 and 24 h pre-Ova or 48 h before Ova challenge and co-administered with Ova. Naïve
(unsensitized and challenged), Ova sensitized and challenged double-saline and double-LPS challenged guinea pigs are also shown. IL-8 was
undetectable in Ova-sensitized and -challenged guinea pigs and was therefore analysed by Kruskal–Wallis non-parametric ANOVA. Results are
expressed as mean ± SEM; n = 5–10. *Significantly different from respective Ova challenge and double-saline treatment group (saline/saline/Ova)
P < 0.05, **P < 0.01, ***P < 0.001; performed with one-way ANOVA followed by Bonferroni post-test. ^^Significantly different from naive animals
P < 0.01, ^^^P < 0.001. ###Significantly different from saline ×2 P < 0.001.
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Sensitivity of inflammatory responses to
inhaled FP
After Ova challenge, vehicle-treated groups displayed an
increase in total inflammatory cells in lavage fluid (Figure 8A)
that was significantly attenuated by treatment with 0.5 and
1 mg·mL−1 FP, but not by 0.05 and 0.1 mg·mL−1 FP (data not
shown). Macrophages (Figure 8B), eosinophils (Figure 8C),
lymphocytes (Figure 8D) and neutrophils (Figure 8E) were
also significantly increased by Ova challenge in vehicle-
treated groups. FP 0.5 and 1 mg·mL−1 FP significantly attenu-
ated eosinophils, macrophages and lymphocytes. After Ova
and LPS pre- and co-administrations (LPS/LPS + Ova), total
and differential cell counts were not significantly reduced by
0.5 or 1 mg·mL−1 FP.
LPS alone also increased total cells, macrophages, lym-
phocytes and neutrophils but not eosinophils. These changes
were not inhibited by 0.5 or 1 mg·mL−1 FP (Figure 8). IL-8
(Figure 8F) was not detectible in Ova alone groups (data not
shown). In Ova and LPS (LPS/LPS + Ova) and LPS alone
groups, 0.5 and 1 mg·mL−1 FP did not significantly attenuate
IL-8. In Ova alone groups, IL-13 levels (Figure 8G) were sig-
nificantly reduced by 0.5 and 1 mg·mL−1 FP compared with
vehicle. In Ova and LPS co-administration groups, 0.5 and
1 mg·mL−1 FP also decreased IL-13 levels compared with
vehicle. IL-17 (Figure 8H) levels were unchanged by 0.5 and
1 mg·mL−1 FP in Ova alone and Ova and LPS (LPS/LPS + Ova)
protocols. Lavage fluid protein levels (Figure 8I) were signifi-
cantly decreased by 0.5 and 1 mg·mL−1 FP after Ova challenge
Figure 5
Bronchiolar changes and goblet cell staining in guinea pigs: naïve (A and E), double-LPS challenged (B and F), Ova sensitized and challenged
treated with either saline (C and G) or LPS 48 h pre-Ova and co-administered with Ova (D and H). ASM, airway smooth muscle; E, epithelium;
IC, inflammatory cell; G, goblet cell; L, lumen. A–D were stained with haematoxylin and eosin, original magnification 100× (bar = 25 μm). E–H
with alcian blue/periodic acid Schiff, original magnification 400× (bar = 100 μm). (I) The mean pathology score of the PB area. (J) The number
of mucin-associated goblet cells per 10 000 epithelial pixels. Results are expressed as mean ± SEM; n = 5–10. *Significantly different from respective
naïve P < 0.05, **P < 0.01, ***P < 0.001 performed with ANOVA followed by Tukey’s post-test. ^Significantly different from saline control
(saline/saline+Ova) P < 0.01.
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compared with vehicle in the LPS/Ova co-administration
group (LPS/LPS + Ova), but not after LPS alone.
Discussion
This study shows that LPS has a complex interaction with
allergen-induced responses, attenuating and exacerbating
them depending on the timing and number of LPS
exposures. This is the first study to examine the effects of
LPS on both inflammatory and functional responses to
allergen challenge. It also demonstrates that LPS decreases
the sensitivity of allergen-induced functional and inflamma-
tory responses to inhaled FP, a mainstay of asthma manage-
ment. As LPS is ubiquitous throughout the environment,
this study highlights how LPS may be an important
modifier of asthma severity and its response to inhaled cor-
ticosteroids.
Figure 6
The mean time courses for changes in sGaw following (A) Ova challenge in sensitized guinea pig (B) treatment with LPS (30 μg·mL−1) 48 h pre-Ova
and co-administered with Ova challenge in sensitized guinea pigs treated with either inhaled vehicle or FP (0.5 or 1 mg·mL−1), split into twice daily
doses. The histogram represents the maximum bronchoconstriction values recorded during the EAR (0–6 h) and LAR (6–12 h). (C) AUC analysis
of sGaw values for 0–12, 0–6 and 6–12 h post-Ova challenge. (D) Analysis of the time taken for EARs to recover to 50% of peak bronchocon-
striction values after Ova and LPS co-administration. Mean changes in sGaw are expressed as mean ± SEM percentage change from baseline prior
to Ova challenge. n = 5–10. *Significantly different from vehicle treatment P < 0.05, performed with ANOVA followed by Dunnett’s post-test.
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The effect of LPS on allergen-induced
functional responses
Variable effects of LPS on allergen-induced functional
responses have been reported previously. LPS can both
decrease EARs (Vannier et al., 1991) and increase the time
taken to reach peak early phase bronchoconstriction (Tulic
et al., 2002). Similarly, LPS can diminish (Komlósi et al., 2006)
or exacerbate (Rodríguez et al., 2003; Delayre-Orthez et al.,
2004) allergen-induced AHR. This is the first reported study to
directly compare the effects of the number and timing of LPS
exposures around the time of allergen challenge on func-
tional responses. We have demonstrated that LPS exposure
24 h before allergen challenge attenuates the EAR, whereas
LPS co-administered with allergen leaves the early phase
response unchanged. The addition of a second LPS exposure
co-administered with Ova prolonged the EAR, an effect pre-
viously unreported. Concordantly, LPS exposure 24 h before
allergen challenge diminished AHR to histamine, whereas
LPS co-administered with allergen prolonged the bronchoc-
onstrictor response to histamine.
Figure 7
Response of the airways to nebulized histamine delivered in a plethysmograph (0.3 mM, 10% duty cycles and 0.5 L·s–1/chamber over 2 min) in
guinea pigs (A) sensitized and challenged with Ova and treated with inhaled vehicle or (B) FP (1 mg·mL−1) split into twice daily doses or (C)
sensitized and challenged with Ova treated with LPS (30 μg·mL−1) 48 h pre-Ova and co-administered with Ova and treated with inhaled vehicle
or (D) FP (1 mg·mL−1) split into twice daily doses or (E) treated with LPS (30 μg·mL−1) twice and treated with inhaled vehicle or (F) FP (1 mg·mL−1),
split into twice daily doses. The histogram represents the maximum bronchoconstriction values recorded during pre- and post-challenge histamine
challenge. Values were recorded pre- and 24 h post-Ova challenge. Mean changes in sGaw are expressed as mean ± SEM percentage change from
baseline. A negative value represents a bronchoconstriction. n = 5–10. *Significantly different from pre-Ova challenge values P < 0.05, **P < 0.01,
***P < 0.001; performed with a two-tailed t-test.
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The EAR is primarily mediated by allergen-induced release
of mast cell-derived bronchoconstrictor mediators including
histamine, LTC4 and TXA2 (Vannier et al., 1991). Mast cells
can also degranulate in response to other stimuli such as LPS
via toll-like receptor (TLR4) activation (Masuda et al., 2002;
Murakami et al., 2007), which can inhibit the EAR following
Ova challenge (Vannier et al., 1991). As the process of regen-
erating preformed mediators following degranulation can
take up to 24 h (Dvorak, 2005), the timing of the LPS expo-
sure may determine the amount of mediators mast cells have
to release in response to allergen challenge. At 24 but not
48 h after LPS exposure mast cells may be largely still
depleted, resulting in limited bronchoconstriction in
response to allergen challenge. Attenuation of the EAR may
also alter later responses to allergen such as the LAR and AHR
that are initiated during the EAR (Smith and Broadley, 2007).
This was observed in the present study where attenuation of
the EAR was accompanied by diminished allergen-induced
AHR. The LAR has been reported to be decreased in rats
following allergen and LPS exposure (Tulic et al., 2002),
although this decrease was only inferred from a decreased
AHR. In humans, exposure to LPS 24 h before allergen chal-
Figure 8
The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) counts in the bronchoalveolar fluid and homogenized lung
(F) IL-13, (G) IL-8 (H) IL-17 and lavage fluid protein levels (I) in guinea pigs sensitized and challenged with Ova, sensitized and challenged with
Ova and treated with LPS (30 μg·mL−1) 48 h pre-Ova and co-administered with Ova or treated with LPS (30 μg·mL−1) twice. Guinea pigs were
treated with either inhaled vehicle or FP (0.5 or 1 mg·mL−1) split into twice daily doses. Naïve (unsensitized and challenged) guinea pigs are also
shown for comparative purposes only. Results are expressed as mean ± SEM; n = 5–10. *Significantly different from respective vehicle P < 0.05,
**P < 0.01, ***P < 0.001; ∧∧∧Significantly different from naïve; performed with ANOVA followed by Dunnett’s post-test or by Kruskal–Wallis
non-parametric test in the case of IL-8.
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lenge did not alter inflammatory or functional AHR responses
to methacholine (Sohy et al., 2006). It is interesting that these
authors used a concentration of LPS (50 μg·mL−1) similar to
that used by ourselves (30 μg·mL−1) and considered that it was
equivalent to the levels found in the environment.
LPS has the potential to potentiate the EAR by increased
mast cell degranulation through enhanced IgE-induced cross-
linking (Masuda et al., 2002). This may underlie the increased
EAR duration in the allergen and LPS co-administration pro-
tocol. However, elongation of the EAR was only observed
after the addition of a second dose of LPS, suggesting that
priming is first required. Indeed, LPS-induced bronchocon-
strictions increase with multiple exposures (Toward and
Broadley, 2002), suggesting a priming action. LPS priming is
mediated by up-regulation of TLR4 and downstream messen-
gers in cells including neutrophils and macrophages (Lin
et al., 2006; Hoogerwerf et al., 2010; Reino et al., 2012). Sub-
sequent doses of LPS then evoke an increased release of bron-
choconstrictive substances (Hoogerwerf et al., 2010).
Neutrophil- and macrophage-derived free radicals cause
epithelial damage and reduce the activity of enzymes such as
histamine N-methyltransferase important in the metabolism
of histamine (Hoshi et al., 1996; Haddad, 2004). This could
extend the biological t1/2 of histamine, prolonging histamine-
induced bronchoconstriction, as observed with LPS and aller-
gen co-administration in the present study. LPS also increases
the production of NO, which can induce AHR (Strohmeier
et al., 2001). However, the lack of activity of iNOS inhibitors
at reducing AHR in other Ova and LPS combination models
would suggest NO is not a critical mediator (Komlósi et al.,
2006).
The effect of LPS on allergen-induced
inflammatory responses and histology
Allergen-induced inflammation is initiated during the EAR
and increases significantly during the LAR, with a predomi-
nance of eosinophils and CD4+ lymphocytes observed (Nabe
et al., 2005). Previous studies have reported that the addition
of LPS exposure local to the respiratory tract at the same time
or after Ova increases total inflammation and the predomi-
nance of neutrophils in both mice (Murakami et al., 2007)
and rats (Tulic´ et al., 2000). Unlike functional responses to
allergen, this effect was not related to the timing of LPS
exposure in the present study, with no difference in the
inflammation found between the two LPS protocols.
However, the total number of cells and macrophages did
increase with an increased number of LPS exposures. This
agrees with a study by Jiang et al. (2006) who showed a
transient increase in neutrophils following i.p. administra-
tion of LPS. But this contrasts with Rodríguez et al. (2003)
who showed that LPS given simultaneously with allergen can
also decrease total cell numbers and not increase neutrophilia
when given systemically by i.v. injection. It was interesting to
note that two exposures of LPS alone produced significant
increases in cells particularly neutrophils and that these levels
were greater than with the LPS/Ova combinations. It might
be argued therefore that there was an inhibition between LPS
and Ova. However, this can be discounted when comparisons
are made between Ova alone and Ova + LPS where the latter
cell levels are clearly significantly greater than with Ova
alone.
Neutrophilia is facilitated by IL-8 and the IL-17 family of
cytokines (Fogli et al., 2013). In particular, IL-17A and KC, the
murine functional homologue for IL-8, have been demon-
strated to be important drivers of increased neutrophilia in a
house dust mite model (de Boer et al., 2012). However, their
importance in Ova and LPS combination responses is rela-
tively unknown. In the present study, increased neutrophilia
in Ova and LPS co-administration protocols coincided with
increased IL-8 but not IL-17A above that observed with Ova
alone, suggesting the former is more important in this model.
However, it does not discount other members of the IL-17
cytokine family being important. IL-8 is a transient cytokine
with levels that fluctuate (Angrisano et al., 2010). This may be
why IL-8 levels were undetectable in naïve animals despite
increased neutrophils after the second LPS exposure.
Allergen challenge promotes a Th2 pattern of inflamma-
tion characterized by eosinophils and cytokines such as IL-13
(Komlósi et al., 2006). In asthma, an altered innate immunity
response to infection and pollutants including LPS appears to
have a role in amplifying the Th2-driven inflammatory
cascade (Holgate, 2012). The effects of LPS on Th2 responses
in animal models of allergy remain uncertain as LPS has been
demonstrated to increase (Delayre-Orthez et al., 2004),
decrease (Gerhold et al., 2002; Rodríguez et al., 2003; Komlósi
et al., 2006) and not alter (Murakami et al., 2007) them. The
timing of LPS exposure or the number of exposures do not
appear to be important in determining the Th2 response as
eosinophil and IL-13 levels were generally unchanged
between protocols. A more crucial factor in the effect of LPS
on Th2 responses is the dose of LPS. Studies reporting
increased Th2 responses often use lower doses of LPS, whereas
decreases are associated with high LPS doses, as used in the
present study, which promote Th1 pro-inflammatory
responses with increased IFN-γ (Gerhold et al., 2002;
Delayre-Orthez et al., 2004).
Airway oedema is a feature of allergic airway inflamma-
tion and worsens during asthma exacerbations (Dougherty
and Fahy, 2009). Airway oedema increased following allergen
challenge as indicated in the present study by the increased
lavage fluid protein. LPS exposure in addition to allergen
challenge in the co-administration protocol further increased
airway oedema. Therefore, our results indicate that both the
timing and dose of LPS exposure are critical for exacerbating
airway oedema. This effect may be mediated by increases in
LPS binding protein in the lavage fluid, which enhances LPS
activation at TLR4 (Dubin et al., 1996).
Mucus secretion is a hallmark of asthma exacerbations
commonly seen in asthmatics that have died from status
asthmaticus (Kuyper et al., 2003). LPS alone increases mucus
production via goblet cell hyperplasia (Toward and Broadley,
2002), although LPS contamination in commercial Ova
during sensitization does not contribute to goblet cell hyper-
plasia (Tsuchiya et al., 2012). In the present study, goblet cell
staining increased after two doses of LPS regardless of admin-
istration protocol and the presence of Ova. This indicates that
the number of LPS exposures is the critical factor in deter-
mining an increase in goblet cells. Histological assessment of
lung pathology revealed that peribronchiolar inflammation
increased following Ova challenge but was not increased
further by the addition of LPS exposure, confirming previous
results (Tsuchiya et al., 2012).
BJP A P P Lowe et al.
2600 British Journal of Pharmacology (2015) 172 2588–2603
Sensitivity to inhaled FP
Inhaled corticosteroids have wide ranging effects on the
inflammatory and functional responses to allergen that con-
tribute to asthma. In this study, FP significantly attenuated
the LAR, AHR and Th2 pulmonary inflammation (IL-13,
eosinophilia) in a dose-dependent manner. As previously
established, FP demonstrated limited effect on the EAR
(Palmqvist et al., 2005). Furthermore, this study established
that the range of FP activity on allergen-induced responses is
relatively narrow, demonstrating full activity at 0.5 mg·mL−1
but no activity at 0.1 mg·mL−1. The effective doses of FP were
then used to determine corticosteroid sensitivity in the LPS/
Ova combination models.
Asthma exacerbations contribute to corticosteroid insen-
sitivity (Ito et al., 2008). The double LPS exposure co-allergen
administration model developed in this study demonstrates
several exacerbated features including elongated EAR, a pro-
longed bronchoconstrictor response to histamine and
increased inflammation, with a predominance of neutrophils.
The sensitivity of this model to inhaled FP was then estab-
lished. Contrasting with effects of inhaled FP on allergen
alone, the highest doses of FP did not reduce LAR, AHR and
cellular inflammation when LPS was added to allergen chal-
lenge. Thus, LPS exposure decreases the sensitivity of allergen-
induced responses to inhaled FP. In contrast, Ova and LPS
combined responses have been reported as partially sensitive
to systemically administered dexamethasone (Komlósi et al.,
2006). Whether this is due to differences in the routes of
administration between studies requires investigation.
The functional and inflammatory responses to LPS alone
seem to be intrinsically less sensitive to inhaled FP, remaining
unchanged in the current study. This has also been observed
in several other studies using single and multiple doses of
inhaled corticosteroids (Trapp et al., 1998; Michel et al.,
2000). However, the FP insensitivity with allergen and LPS is
not simply due to any intrinsic inhaled corticosteroid insen-
sitivity of LPS-induced inflammation as features of allergen-
induced inflammation such as eosinophils were also rendered
insensitive.
Neutrophils are observed in increased numbers in
corticosteroid-insensitive asthmatics (McKinley et al., 2008).
The neutrophilic nature of the inflammatory response in
these people may contribute to corticosteroid insensitivity as
neutrophils are less sensitive to corticosteroids then other
inflammatory cell types (Strickland et al., 2001; Uddin et al.,
2010). Moreover, they release a range of granule products and
inflammatory mediators that increase the oxidative and
nitroxic burden on the airways (Ito et al., 2008). This can
up-regulate glucocorticoid receptor-β, decrease histone
deacetylase-2 activity and increase PI3K/Akt pathway activa-
tion, all of which can reduce corticosteroid sensitivity
(Strickland et al., 2001; Ito et al., 2008; Mercado et al., 2011).
Neutrophilia in steroid-insensitive mice is associated with
high levels of IL-8 and IL-17 (McKinley et al., 2008), which
are likely to be important in sustaining the raised neutro-
philia observed with allergen and LPS co-administration.
Indeed, IL-8 levels were raised significantly above naïve levels
by Ova and LPS co-administration.
Corticosteroid insensitivity in asthma lies on a spectrum,
with complete resistance rare (Szefler et al., 2002). The
current study suggests that the insensitivity in the allergen/
LPS model may be due to a rightwards shift in the dose–
response curve to FP rather than complete resistance. At the
highest dose of FP, a non-significant reduction in the LAR was
observed. There is also evidence that certain populations of
cells such as lymphocytes (Yang et al., 2009) may remain
steroid sensitive, and here cell-released mediators such as
IL-13 were still reduced by FP. The present study revealed
non-significant reductions in lymphocyte numbers with FP,
suggesting that differentiation of lymphocyte types may
reveal steroid-sensitive populations. Finally, FP continued to
reduce levels of total protein in lavage fluid with the allergen
and LPS combination model, as with allergen alone.
However, this effect could be mediated by non-genomic path-
ways. Corticosteroids decrease uptake of noradrenaline at
sympathetic synapses, potentiating noradrenaline’s action at
α1-adrenoceptors, promoting vasoconstriction and thereby
decreasing fluid extravasation (Wanner et al., 2004).
However, as FP was unable to reduce lavage fluid protein
induced by LPS alone in the present and previous studies
(O’Leary et al., 1996), the mechanism behind this effect may
be more complicated. Although this model exhibited insen-
sitivity to inhaled FP, we have shown that there is normal
sensitivity to systemically administered dexamethasone
(Lowe et al., 2013).
Conclusions
This study demonstrated that LPS had dichotomous effects
on allergen-induced airway function and inflammation
determined by the timing and number of LPS exposures. The
ability of LPS to exacerbate airway inflammation, worsen
airway function and decrease corticosteroid sensitivity has
important implications. The widespread presence of LPS in
the environment probably makes it a significant contributor
in the development of asthma exacerbations and corticoster-
oid insensitivity in humans. An increased understanding of
how LPS contributes to these processes could lead to novel
treatments in an area of unmet clinical need.
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